Yahoo Finance 
Hypoglycemia Drug Pipeline Research 2024: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Hypoglycemia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Hypoglycemia - Pipeline Insight, 2024" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Hypoglycemia pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space."Hypoglycemia- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypoglycemia pipeline landscape is provided which includes the disease overview and Hypoglycemia treatment guidelines.
The assessment part of the report embraces, in depth Hypoglycemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypoglycemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Hypoglycemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypoglycemia.
Hypoglycemia Emerging Drugs Chapters
This segment of the Hypoglycemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypoglycemia Emerging Drugs
RZ358: Rezolute
RZ358 is a fully human monoclonal antibody that works downstream from the pancreas and other sources of insulin or related paraneoplastic substances, and instead binds to a unique allosteric site on insulin receptors in the liver, fat, and muscle. The antibody counteracts excess insulin receptor activation by insulin and other effector substances (such as IGF-2), thereby improving hypoglycemia.
Because RZ358 acts downstream from the pancreas at the insulin receptor, it has the potential to be universally effective at treating hypoglycemia due to congenital HI, regardless of the causative genetic defect, as well as acquired forms of HI such as those mediated by insulinomas (ICTs) and other tumor types (NICTs). Currently, the drug is in Phase III stage of its clinical trial for the treatment of hypoglycemia.
VX-880: Vertex Pharmaceuticals
VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. It is being evaluated for patients who have type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 is being investigated as an infusion into the hepatic portal vein and requires immunosuppressive therapy to protect the islet cells from immune rejection. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of hypoglycemia.
Hypoglycemia: Therapeutic Assessment
This segment of the report provides insights about the different Hypoglycemia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Hypoglycemia
There are approx. 6+ key companies which are developing the therapies for Hypoglycemia. The companies which have their Hypoglycemia drug candidates in the most advanced stage, i.e. Phase III include, Rezolute.
Key Questions
How many companies are developing Hypoglycemia drugs?
How many Hypoglycemia drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypoglycemia?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypoglycemia therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Hypoglycemia and their status?
What are the key designations that have been granted to the emerging drugs?
Key Players
Rezolute
Vertex Pharmaceuticals
MBX Biosciences
Eli Lilly and Company
Key Products
RZ 358
VX-880
MBX 1416
Tirzepatide
Phases
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Molecule Type
Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Product Type
Hypoglycemia Report Insights
Hypoglycemia Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Hypoglycemia Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/ay84zz
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
